Kiniksa Pharmaceuticals International (KNSA) Competitors $37.13 +0.12 (+0.32%) As of 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, LEGN, and ABVXShould you be buying Kiniksa Pharmaceuticals International stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals International include BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals International vs. Its Competitors BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends. Is KNSA or BBIO more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to BridgeBio Pharma's net margin of -329.25%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat BridgeBio Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% BridgeBio Pharma -329.25%N/A -85.69% Do analysts recommend KNSA or BBIO? Kiniksa Pharmaceuticals International presently has a consensus target price of $41.17, suggesting a potential upside of 10.87%. BridgeBio Pharma has a consensus target price of $63.94, suggesting a potential upside of 24.70%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in KNSA or BBIO? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, KNSA or BBIO? Kiniksa Pharmaceuticals International has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Does the media favor KNSA or BBIO? In the previous week, BridgeBio Pharma had 14 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 32 mentions for BridgeBio Pharma and 18 mentions for Kiniksa Pharmaceuticals International. BridgeBio Pharma's average media sentiment score of 1.03 beat Kiniksa Pharmaceuticals International's score of 0.92 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 18 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, KNSA or BBIO? Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M6.50-$43.19M$0.04928.25BridgeBio Pharma$221.90M44.18-$535.76M-$4.09-12.54 SummaryKiniksa Pharmaceuticals International beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.75B$3.15B$5.82B$10.17BDividend YieldN/A2.32%5.69%4.60%P/E Ratio927.9121.4374.6725.98Price / Sales6.50256.94454.5485.61Price / CashN/A45.3337.0859.91Price / Book5.639.6512.186.31Net Income-$43.19M-$53.29M$3.29B$270.86M7 Day Performance3.98%0.44%1.08%3.46%1 Month Performance13.27%9.06%7.32%6.57%1 Year Performance51.61%13.13%63.11%28.39% Kiniksa Pharmaceuticals International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International2.2602 of 5 stars$37.13+0.3%$41.17+10.9%+52.1%$2.75B$423.24M927.91220Short Interest ↑BBIOBridgeBio Pharma4.4486 of 5 stars$51.76-1.5%$62.18+20.1%+87.9%$9.89B$221.90M-12.66400Positive NewsAnalyst ForecastMRNAModerna4.5036 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.24B-3.205,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1652 of 5 stars$105.91+0.0%$109.00+2.9%+252.9%$9.16B$42.28M-106.9830Positive NewsELANElanco Animal Health2.6335 of 5 stars$18.38-0.4%$17.33-5.7%+29.8%$9.12B$4.44B21.379,000Positive NewsHigh Trading VolumeROIVRoivant Sciences2.9462 of 5 stars$11.93-0.1%$16.50+38.3%+16.4%$8.15B$29.05M-17.04860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.2417 of 5 stars$37.97-0.9%$69.92+84.2%+11.0%$7.10B$11.58M-8.44250Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols4.0254 of 5 stars$9.97+1.0%$10.30+3.3%+9.0%$6.85B$7.81B8.5223,822News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.1774 of 5 stars$103.15-1.0%$101.57-1.5%+98.6%$6.85B$130.13M-34.27140Positive NewsLEGNLegend Biotech3.2748 of 5 stars$34.73+1.0%$74.22+113.7%-32.0%$6.41B$627.24M-39.472,609Positive NewsABVXAbivax2.3345 of 5 stars$81.03-0.7%$92.33+13.9%+631.6%$6.12BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap Down Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Abivax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNSA Stock Alerts